English
Cohance Lifesciences Q1 Results
- BSE: 543064
- NSE: COHANCE
- ISIN: INE03QK01018
- Sector: Biotechnology & Drugs
BSE
528.25
-7.00 (-1.31%)
-7.00 (-1.31%)Volume19.39 K
Updated: Wed 10 Dec, 2025 | 15:50:11
NSE
528.45-6.55 (-1.22%)
-6.55 (-1.22%)Volume3.90 L
Updated: Wed 10 Dec, 2025 | 15:55:23
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q1 Results Highlights
Note: Comparison is on QoQ basis
Quarterly - Cohance Lifesciences Q1 Results
*All figures in crores except per share values
| Fiscal Period | Jun 25 | Mar 25 | QoQ Comp | Jun 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 490.54 | 355.24 | 38.09% | 394.26 | 24.42% |
| Depreciation/ Amortization | 45.14 | 26.78 | 68.56% | 31.28 | 44.31% |
| Operating Income | 58.77 | 46.78 | 25.63% | 93.82 | -37.36% |
| Net Income | 48.88 | 42.01 | 16.35% | 75.37 | -35.15% |
| Other Operating Expenses Total | 155.84 | 105.38 | 47.88% | 112.94 | 37.98% |
| Net Income Before Taxes | 62.76 | 51.60 | 21.63% | 103.03 | -39.09% |
| Total Revenue | 549.31 | 402.02 | 36.64% | 488.08 | 12.55% |
| Selling/ General/ Admin Expenses Total | 133.32 | 89.08 | 49.66% | 95.89 | 39.03% |
| Diluted Normalized EPS | 1.43 | 1.64 | -13.15% | 1.97 | -27.64% |
EQUITY QUICK LINKS
FROM MARKETS
Trending Stocks
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.